Mark J Eisenberg1,2,3, Andréa Hébert-Losier1, Sarah B Windle1, Todd Greenspoon4, Tim Brandys5, Tamàs Fülöp6, Thang Nguyen7, Stéphane Elkouri8, Martine Montigny9, Igor Wilderman10, Olivier F Bertrand11, Joanna Alexis Bostwick12, John Abrahamson13, Yves Lacasse11, Smita Pakhale14, Josselin Cabaussel1, Kristian B Filion1,2. 1. Lady Davis Institute, Jewish General Hospital, Montréal, Québec, Canada. 2. Departments of Medicine and Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada. 3. Division of Cardiology, Jewish General Hospital, Montréal, Québec, Canada. 4. Hamilton Community Health Centre, Family Health Organization, Hamilton, Ontario, Canada. 5. Ottawa Hospital, Ottawa, Ontario, Canada. 6. Centre de recherche sur le vieillissement, Sherbrooke, Québec, Canada. 7. St Boniface Hospital, Winnipeg, Manitoba, Canada. 8. Division of Vascular Surgery, Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada. 9. Centre intégré de santé et de services sociaux de Laval, Hôpital Cité-de-la-Santé, Laval, Québec, Canada. 10. Wilderman Medical Clinic/Canadian Centre for Clinical Trials, Thornhill, Ontario, Canada. 11. Institut de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec City, Québec, Canada. 12. Hôpital Montfort, Ottawa, Ontario, Canada. 13. Michael Garron Hospital, Toronto, Ontario, Canada. 14. The Ottawa Hospital Research Institute/The Bridge Engagement Centre, Ottawa, Ontario, Canada.
Abstract
Importance: Electronic cigarettes (e-cigarettes) for smoking cessation remain controversial. Objective: To evaluate e-cigarettes with individual counseling for smoking cessation. Design, Setting, and Participants: A randomized clinical trial enrolled adults motivated to quit smoking from November 2016 to September 2019 at 17 Canadian sites (801 individuals screened; 274 ineligible and 151 declined). Manufacturing delays resulted in early termination (376/486 participants, 77% of target). Outcomes through 24 weeks (March 2020) are reported. Interventions: Randomization to nicotine e-cigarettes (n = 128), nonnicotine e-cigarettes (n = 127), or no e-cigarettes (n = 121) for 12 weeks. All groups received individual counseling. Main Outcomes and Measures: The primary end point was point prevalence abstinence (7-day recall, biochemically validated using expired carbon monoxide) at 12 weeks, changed from 52 weeks following early termination. Participants missing data were assumed to be smoking. The 7 secondary end points, examined at multiple follow-ups, were point prevalence abstinence at other follow-ups, continuous abstinence, daily cigarette consumption change, serious adverse events, adverse events, dropouts due to adverse effects, and treatment adherence. Results: Among 376 randomized participants (mean age, 52 years; 178 women [47%]), 299 (80%) and 278 (74%) self-reported smoking status at 12 and 24 weeks, respectively. Point prevalence abstinence was significantly greater for nicotine e-cigarettes plus counseling vs counseling alone at 12 weeks (21.9% vs 9.1%; risk difference [RD], 12.8 [95% CI, 4.0 to 21.6]) but not 24 weeks (17.2% vs 9.9%; RD, 7.3 [95% CI, -1.2 to 15.7]). Point prevalence abstinence for nonnicotine e-cigarettes plus counseling was not significantly different from counseling alone at 12 weeks (17.3% vs 9.1%; RD, 8.2 [95% CI, -0.1 to 16.6]), but was significantly greater at 24 weeks (20.5% vs 9.9%; RD, 10.6 [95% CI, 1.8 to 19.4]). Adverse events were common (nicotine e-cigarette with counseling: 120 [94%]; nonnicotine e-cigarette with counseling: 118 [93%]; counseling only: 88 [73%]), with the most common being cough (64%) and dry mouth (53%). Conclusions and Relevance: Among adults motivated to quit smoking, nicotine e-cigarettes plus counseling vs counseling alone significantly increased point prevalence abstinence at 12 weeks. However, the difference was no longer significant at 24 weeks, and trial interpretation is limited by early termination and inconsistent findings for nicotine and nonnicotine e-cigarettes, suggesting further research is needed. Trial Registration: ClinicalTrials.gov Identifier: NCT02417467.
RCT Entities:
Importance: Electronic cigarettes (e-cigarettes) for smoking cessation remain controversial. Objective: To evaluate e-cigarettes with individual counseling for smoking cessation. Design, Setting, and Participants: A randomized clinical trial enrolled adults motivated to quit smoking from November 2016 to September 2019 at 17 Canadian sites (801 individuals screened; 274 ineligible and 151 declined). Manufacturing delays resulted in early termination (376/486 participants, 77% of target). Outcomes through 24 weeks (March 2020) are reported. Interventions: Randomization to nicotine e-cigarettes (n = 128), nonnicotine e-cigarettes (n = 127), or no e-cigarettes (n = 121) for 12 weeks. All groups received individual counseling. Main Outcomes and Measures: The primary end point was point prevalence abstinence (7-day recall, biochemically validated using expired carbon monoxide) at 12 weeks, changed from 52 weeks following early termination. Participants missing data were assumed to be smoking. The 7 secondary end points, examined at multiple follow-ups, were point prevalence abstinence at other follow-ups, continuous abstinence, daily cigarette consumption change, serious adverse events, adverse events, dropouts due to adverse effects, and treatment adherence. Results: Among 376 randomized participants (mean age, 52 years; 178 women [47%]), 299 (80%) and 278 (74%) self-reported smoking status at 12 and 24 weeks, respectively. Point prevalence abstinence was significantly greater for nicotine e-cigarettes plus counseling vs counseling alone at 12 weeks (21.9% vs 9.1%; risk difference [RD], 12.8 [95% CI, 4.0 to 21.6]) but not 24 weeks (17.2% vs 9.9%; RD, 7.3 [95% CI, -1.2 to 15.7]). Point prevalence abstinence for nonnicotine e-cigarettes plus counseling was not significantly different from counseling alone at 12 weeks (17.3% vs 9.1%; RD, 8.2 [95% CI, -0.1 to 16.6]), but was significantly greater at 24 weeks (20.5% vs 9.9%; RD, 10.6 [95% CI, 1.8 to 19.4]). Adverse events were common (nicotine e-cigarette with counseling: 120 [94%]; nonnicotine e-cigarette with counseling: 118 [93%]; counseling only: 88 [73%]), with the most common being cough (64%) and dry mouth (53%). Conclusions and Relevance: Among adults motivated to quit smoking, nicotine e-cigarettes plus counseling vs counseling alone significantly increased point prevalence abstinence at 12 weeks. However, the difference was no longer significant at 24 weeks, and trial interpretation is limited by early termination and inconsistent findings for nicotine and nonnicotine e-cigarettes, suggesting further research is needed. Trial Registration: ClinicalTrials.gov Identifier: NCT02417467.
Authors: Scott D Halpern; Michael O Harhay; Kathryn Saulsgiver; Christine Brophy; Andrea B Troxel; Kevin G Volpp Journal: N Engl J Med Date: 2018-05-23 Impact factor: 91.245
Authors: Matthew J Carpenter; Bryan W Heckman; Amy E Wahlquist; Theodore L Wagener; Maciej L Goniewicz; Kevin M Gray; Brett Froeliger; K Michael Cummings Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-10 Impact factor: 4.254
Authors: Boris Reidel; Giorgia Radicioni; Phillip W Clapp; Amina A Ford; Sabri Abdelwahab; Meghan E Rebuli; Prashamsha Haridass; Neil E Alexis; Ilona Jaspers; Mehmet Kesimer Journal: Am J Respir Crit Care Med Date: 2018-02-15 Impact factor: 21.405
Authors: Benjamin C Blount; Mateusz P Karwowski; Peter G Shields; Maria Morel-Espinosa; Liza Valentin-Blasini; Michael Gardner; Martha Braselton; Christina R Brosius; Kevin T Caron; David Chambers; Joseph Corstvet; Elizabeth Cowan; Víctor R De Jesús; Paul Espinosa; Carolina Fernandez; Cory Holder; Zsuzsanna Kuklenyik; Jennifer D Kusovschi; Cody Newman; Gregory B Reis; Jon Rees; Chris Reese; Lalith Silva; Tiffany Seyler; Min-Ae Song; Connie Sosnoff; Carleen R Spitzer; Denise Tevis; Lanqing Wang; Cliff Watson; Mark D Wewers; Baoyun Xia; Douglas T Heitkemper; Isaac Ghinai; Jennifer Layden; Peter Briss; Brian A King; Lisa J Delaney; Christopher M Jones; Grant T Baldwin; Anita Patel; Dana Meaney-Delman; Dale Rose; Vikram Krishnasamy; John R Barr; Jerry Thomas; James L Pirkle Journal: N Engl J Med Date: 2019-12-20 Impact factor: 91.245
Authors: Mohammad Siahpush; Raees A Shaikh; Molly McCarthy; Asia Sikora Kessler; Melissa Tibbits; Gopal K Singh Journal: BMJ Open Date: 2015-01-13 Impact factor: 2.692
Authors: Elise E DeVito; Tessa Fagle; Alicia M Allen; Raina D Pang; Nicole Petersen; Philip H Smith; Andrea H Weinberger Journal: Curr Addict Rep Date: 2021-07-13
Authors: Loren E Wold; Robert Tarran; Evan W Neczypor; Matthew J Mears; Arunava Ghosh; M Flori Sassano; Richard J Gumina Journal: Circulation Date: 2022-01-18 Impact factor: 29.690
Authors: Krishna P Reddy; Eli Schwamm; Sara Kalkhoran; Farzad Noubary; Rochelle P Walensky; Nancy A Rigotti Journal: Am J Respir Crit Care Med Date: 2021-07-15 Impact factor: 30.528